CHICAGO, Sept. 25, 2017 (GLOBE NEWSWIRE) — Tempus announced today that it closed a $70M, Series C, round of venture funding co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M.
Tempus has spent the last two years building a series of data pipelines to collect, cleanse, and analyze data at scale, utilizing the most sophisticated technologies, including cloud-based platform, cluster computing, next generation sequencing, natural language processing and AI-assisted image recognition. These data pipelines, in turn, power proprietary software applications designed to drive clinical decision support and cutting edge academic research.
“In oncology, and across healthcare more broadly, datasets have historically been small and disorganized,” said Eric Lefkofsky, Founder and CEO at Tempus. “Thankfully, technology has opened the door to new possibilities and for the first time in history, it is possible to amass massive amounts of molecular and clinical data and put it to work for the benefit of patients.”
“We are thrilled to have led an investment in Tempus,” said NEA’s Peter Barris. “Given NEA’s long and successful history investing in the intersection of technology and life science, we felt like the perfect strategic partner given Tempus’s mission to help doctors personalize care by collecting and analyzing large volumes of data.”
With collaborations already in place with leading hospitals such as Cleveland Clinic, Duke University School of Medicine, Mayo Clinic, Northwestern’s Lurie Cancer Center, Penn’s Abramson Cancer Center, University of Chicago Medicine, University of Michigan and community hospitals across the country, the Tempus platform offers physicians, and patients, the world’s largest library of clinical and molecular data to personalize and improve cancer care.
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.